The phrase "you have cancer" is a life-altering inflection point for any individual. However, for a small but significant percentage of patients, the diagnosis carries an even heavier weight: Stage 4. This is the reality of Metastatic Breast Cancer (MBC), a condition where the disease has already migrated beyond the breast tissue to distant organs by the time it is first identified.
Miriam Sabo was 42 years old when she received this news. Her diagnosis was "de novo" metastatic, meaning the cancer had already reached her liver at the moment of discovery. Today, 6.5 years after that harrowing day, Sabo’s story serves as a profound testament to the changing landscape of MBC—a landscape defined not by a quest for a "cure" in the traditional sense, but by the pursuit of a meaningful, sustained life while undergoing continuous treatment.
Main Facts: Redefining the MBC Narrative
Metastatic breast cancer, also known as Stage 4, occurs when cancer cells break away from the original tumor site and travel through the blood or lymphatic system to form new tumors in other parts of the body. In Sabo’s case, the destination was her liver.
One of the most critical distinctions in Sabo’s journey is the terminology used to describe her condition. While many in the medical community and the public use the word "terminal," Sabo and many advocates prefer the term "non-curative." This distinction is more than semantic; it represents a shift in how the disease is managed. Unlike earlier stages of breast cancer, where the goal is to undergo a set course of treatment (surgery, chemotherapy, radiation) and reach remission, MBC requires what Sabo calls "forever treatment."
The "De Novo" Distinction
Approximately 6% of women are metastatic at the time of their initial breast cancer diagnosis. This is referred to as de novo metastatic breast cancer. For these patients, there is no "before" period of early-stage survivorship; their entry into the world of oncology begins at the most advanced level.
The Role of Support Systems
Central to Sabo’s experience has been Sharsheret, a national non-profit organization that provides support to Jewish women and families facing breast and ovarian cancer. Sabo utilized Sharsheret’s "Embrace" program, specifically designed for those living with metastatic disease. Through this program, she found not only clinical resources but also a psychological "sounding board" in social workers and peer supporters who understood the unique existential weight of a non-curative diagnosis.
Chronology: A 6.5-Year Journey of Resilience
The timeline of Miriam Sabo’s life with MBC defies the grim expectations often found in outdated medical literature. Her journey can be mapped through both medical milestones and personal triumphs.
The Initial Shock (October 2018)
At age 42, Sabo’s life was upended. Despite having previously tested negative for the BRCA gene mutation—a common risk factor—she was diagnosed with Stage 4 cancer. The immediate aftermath was a period of intense uncertainty. "Little can prepare you when you’re told ‘You have cancer’… but nothing prepares you for being told ‘You have Stage 4 Breast Cancer,’" Sabo recalls.
The Integration of Sharsheret (Early 2019)
Recognizing that she needed a "cancer team" that extended beyond oncologists and surgeons, Sabo reached out to Sharsheret. She was paired with Rachel, a social worker, and Bonnie, the head of the Embrace program. These connections provided the emotional infrastructure necessary to navigate a life of perpetual treatment.
The Shift to Advocacy (2020–2021)
As Sabo moved past the two-year mark—a significant milestone in metastatic care—she transitioned from a seeker of support to a provider of it. Encouraged by her team at Sharsheret, she became a peer supporter, helping other women navigate the specific anxieties of MBC, such as "scanxiety" (the fear associated with regular imaging) and the fatigue of chronic therapy.
Living Through Milestones (2022–2025)
Over the last several years, Sabo has defied the "expiration date" mentality. She has witnessed her four children grow, attended their graduations, and celebrated the weddings of two of them. Her 6.5-year survival period represents a significant victory in the context of metastatic liver involvement, which historically carried a much shorter prognosis.
Supporting Data: The Changing Landscape of MBC
Sabo’s experience is mirrored by broader trends in oncology, though she remains an outlier in terms of long-term stability with liver metastasis.
Survival Statistics and the "Google Gap"
Sabo’s advice to avoid "Googling the statistics" is rooted in the fact that many online survival rates are based on retrospective data that does not account for the most recent breakthroughs in targeted therapies.
- The 5-Year Survival Rate: According to the American Cancer Society, the 5-year relative survival rate for metastatic breast cancer in the United States is currently around 31%. However, this number is an average; individual outcomes vary wildly based on the subtype of cancer (HER2-positive, ER/PR-positive, or Triple Negative).
- The Rise of Long-Term Survivors: There is a growing cohort of "long-term thrivers" who live five, ten, or even fifteen years with metastatic disease due to the advent of CDK4/6 inhibitors, immunotherapy, and more effective HER2-targeted agents.
The Prevalence of De Novo Cases
While screening has improved, the rate of de novo metastatic breast cancer has remained relatively stable at 6-10%. Researchers are still investigating why some cancers bypass the early stages entirely, emphasizing the need for better systemic detection methods beyond localized mammography.
Official Responses: The Importance of Psychosocial Care
Organizations like Sharsheret and the Metastatic Breast Cancer Network (MBCN) emphasize that medical treatment is only one pillar of care. The "official response" from the psychosocial community highlights a critical gap in the traditional "Pink Ribbon" narrative.
The Embrace Program Perspective
Sharsheret’s Embrace program was developed in response to the feedback that metastatic patients often feel isolated in general breast cancer support groups. In those groups, the focus is often on "finishing" treatment and "winning the battle." For a metastatic patient, there is no finish line.
"Rachel and Bonnie [at Sharsheret] were a sounding board for every rambling thought I had," Sabo noted. This level of specialized counseling is now considered a best practice in "Whole Person" oncology, which integrates mental health professionals into the primary care team.
Medical Motto: "I Am Not Milk"
Sabo’s personal motto—"I’m not milk; there’s no expiration date stamped on me"—reflects a growing movement among oncologists to treat MBC as a chronic condition, similar to diabetes or heart disease, rather than an immediate death sentence. Medical professionals now focus on the "sequential use" of drugs, moving a patient from one treatment to the next as the cancer evolves, thereby extending life for years or even decades.
Implications: The Future of Metastatic Advocacy
The implications of Miriam Sabo’s 6.5-year journey extend far beyond her personal life. Her story highlights several critical shifts in the public health approach to breast cancer.
1. Moving Beyond Awareness to Research
For decades, breast cancer advocacy focused on "awareness" and early detection. While successful, this focus often marginalized the 30% of early-stage patients who eventually progress to Stage 4, as well as those diagnosed de novo. Sabo’s story underscores the necessity of funding research specifically for metastatic disease, which receives only about 7-10% of total breast cancer research funding despite being the only stage that results in death.
2. The Mental Health of "Forever Treatment"
Living in a state of "non-curative" health creates a unique psychological burden. Patients must balance the joy of milestones (like weddings and graduations) with the physical toll of continuous medication and the looming threat of the next scan. Sabo’s reliance on her faith and her support network highlights the need for long-term mental health resources for chronic cancer patients.
3. Redefining "Good" Outcomes
Sabo’s perspective—that "G-d’s plans are always for good, even in the hardest of moments"—reflects a shift in the definition of a successful medical outcome. Success is no longer measured solely by the absence of disease, but by the quality of life and the ability of the patient to remain present for their family’s "day-in and day-out moments."
4. The Peer-Support Revolution
By becoming a peer supporter, Sabo is part of a revolution in patient care where "lived experience" is viewed as a vital clinical tool. Peer supporters can provide practical advice on managing side effects and emotional navigation that even the best-trained physicians cannot offer.
Conclusion
Miriam Sabo’s journey from a 42-year-old shocked by a Stage 4 diagnosis to a 48-year-old advocate and matriarch is a powerful rebuttal to the stigma of metastatic breast cancer. While the disease remains non-curative and the challenges are immense, her story proves that life does not end with a Stage 4 diagnosis; it changes.
As Sabo continues her "forever treatment," her presence at her children’s weddings and her work with Sharsheret serve as a beacon for the thousands of women diagnosed each year. She remains a living reminder that while statistics provide a map of the past, they do not dictate the path of the individual. In the world of metastatic breast cancer, hope is not found in the absence of disease, but in the strength to live fully in spite of it.
About the Author
